{"id":90624,"date":"2026-05-05T06:27:21","date_gmt":"2026-05-05T06:27:21","guid":{"rendered":"https:\/\/diyhaven858.wasmer.app\/index.php\/johnson-johnson-advances-ibd-therapy-despite-trial-miss\/"},"modified":"2026-05-05T06:27:21","modified_gmt":"2026-05-05T06:27:21","slug":"johnson-johnson-advances-ibd-therapy-despite-trial-miss","status":"publish","type":"post","link":"https:\/\/diyhaven858.wasmer.app\/index.php\/johnson-johnson-advances-ibd-therapy-despite-trial-miss\/","title":{"rendered":"Johnson &#038; Johnson advances IBD therapy, despite trial miss"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div data-author=\"allison-deangelis\">\n<p class=\"author-bio\">Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.  You can reach Allison on Signal at AllisonDeAngelis.01.<\/p>\n<\/div>\n<div>\n<p>A closely watched therapy developed by Johnson &amp; Johnson failed to show a statistically meaningful improvement for patients with inflammatory bowel disease. But the company plans to advance the drug into late-stage testing, focusing on a growing subgroup of patients.\u00a0<\/p>\n<p>On Tuesday, trial investigators presented the results of Johnson &amp; Johnson\u2019s DUET study, testing how well combining the drugs Tremfya and Simponi would stop the immune system from mistakenly attacking healthy tissues in the digestive tract. It\u2019s a follow-up to a 2022 clinical trial that showed a significant benefit to patients, nearly doubling the rates of disease remission and spurring several companies to start developing combination approaches for IBD.\u00a0<\/p>\n<p>Johnson &amp; Johnson tested its combined therapy, dubbed JNJ-4804, in two Phase 2b clinical trials hitting both major forms of inflammatory bowel disease \u2014 ulcerative colitis and Crohn\u2019s disease. In each trial, the combination therapy performed better than the individual drugs, but did not meet the primary endpoint of clinical remission.\u00a0<\/p>\n<div class=\"restricted-content-breaker article\" aria-labelledby=\"restricted-story-heading\" aria-describedby=\"restricted-story-description\" checked=\"false\">\n<div class=\"restricted-content-breaker-bar\">\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? Log in<\/p>\n<\/p><\/div>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<div class=\"restricted-content-breaker-wrapper\">\n\t\t\t\t<span class=\"stat-paywall-archive\"><\/p>\n<p>\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t<\/span><\/p>\n<h2 id=\"restricted-story-heading\">This article is exclusive to STAT+ subscribers<\/h2>\n<h3 id=\"restricted-story-description\">Unlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/h3>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? Log in<\/p>\n<div class=\"restricted-content-breaker-cards\">\n<div class=\"slider-container\" aria-label=\"Subscription plan toggle\">\n\t\t\t\t\t\t<button type=\"button\" class=\"individual\" aria-pressed=\"false\">Individual plans<\/button><\/p>\n<p>\t\t\t\t\t\t<button type=\"button\" class=\"group\" aria-pressed=\"false\">Group plans<\/button>\n\t\t\t\t\t<\/div>\n<\/p><\/div>\n<p>\t\t\t\tView All Plans\n\t\t\t<\/p><\/div>\n<\/p><\/div>\n<div class=\"restricted-message-breaker\">\n<div class=\"restricted-content-wrapper\">\n<div class=\"restricted-content-message\">\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\tSubscribe\n\t\t\t\t\t\t\t\t\t<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. A closely watched therapy developed by Johnson &amp; Johnson failed to show a statistically meaningful [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":90625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-90624","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/05\/GettyImages-2270734405-1024x576.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/90624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=90624"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/90624\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/90625"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=90624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=90624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=90624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}